N6-methyladenosine-modified long non-coding RNA KIF9-AS1 promotes stemness and sorafenib resistance in hepatocellular carcinoma by upregulating SHOX2 expression

Table 1 The primer sequence in quantitative reverse transcription polymerase chain reaction

Genes	Sequence (5’-3’)
KIF9-AS1 F	TCCCTGCTGAAGTGACAGTG
KIF9-AS1 R	ACCCCAACCCTCTCTGTTCT
SHOX2 F	GCCTTCATGCGAGAGGAACT
SHOX2 R	CGCCTGAACCTGCTGAAATG
PD-L1 F	ACCACCACCAATTCCAAGAG
PD-L1 R	GATGGCTCCCAGAATTACCA
GAPDH F	CCAGGTGGTCTCCTCTGA
GAPDH R	GCTGTAGCCAAATCGTTGT

SHOX2: Short stature homeobox 2; PD-L1: Programmed death-ligand 1; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

Table 2 Association between long non-coding RNA KIF9-AS1 expression and clinical features of hepatocellular carcinoma patients

Clinical features	Cases (n = 20)	LncRNA KIF9-AS1		P value
		High (n = 10)	Low (n = 10)
Gender				0.3698
Male	11	4	7
Female	9	6	3
Age (years)				0.6499
< 65	8	5	3
≥ 65	12	5	7
TNM stage				0.0055b
Stage 1/2	11	2	9
Stage 3/4	9	8	1
Tumor size (cm)				0.6285
< 5	14	6	8
≥ 5	6	4	2
Lymph node metastasis				0.0198a
Positive	8	7	1
Negative	12	3	9

^aP < 0.05.

^bP < 0.05.

LncRNA: Long noncoding RNA; TNM: Tumor-node-metastasis.